Q-omics provides the consensus-scored MYEF2 profile across patient tissues and cancer cell-line models. MYEF2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MYEF2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, MYEF2 protein abundance shows 24,021 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight PAAD, THCA, and GBM as cancer lineages where MYEF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYEF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYEF2 survival associations across molecular data types. MYEF2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYEF2 RNA expression–survival associations across cancer types. High MYEF2 expression shows unfavorable associations in ACC, LIHC and MESO, but favorable associations in PAAD, HNSC and KIRC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for MYEF2 RNA expression.
This table summarizes MYEF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYEF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYEF2 shows lower tumor expression in LUSC and KIRC and higher tumor expression in THCA, BRCA, CHOL and LIHC. The THCA box plot shows higher MYEF2 RNA expression in tumor versus normal tissue (log2 FC = +1.352, t-test p < 0.001).
This table shows molecular features associated with MYEF2 in patient tissues and cancer cell lines. In patient samples, MYEF2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYEF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
